相关临床试验
690
75 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
31
4.5%
已完成
396
57.4%
Enrolling By Invitation
7
1.0%
No Longer Available
1
0.1%
尚未招募
37
5.4%
招募中
93
13.5%
暂停
3
0.4%
终止
50
7.3%
Unknown
42
6.1%
撤回
30
4.3%
暂无批准数据
- Patient advocates and medical experts are urging Oregon lawmakers to pass legislation in 2027 requiring health insurers to cover FDA-approved biomarker testing. - Biomarker tests can detect diseases like Alzheimer's and cancer through tissue, blood, or fluid samples, enabling personalized and targeted treatment strategies. - Nearly half of U.S. states already mandate biomarker test coverage, and Oregon advocates argue the state should join them to improve patient outcomes. - Personal testimonies from an Alzheimer's patient and an OHSU oncologist highlight how biomarker testing led to accurate diagnoses and effective targeted therapies.
- Bassett Research Institute has been awarded approximately $12 million from PCORI to conduct a multi-center clinical trial examining kidney effects of vancomycin and piperacillin/tazobactam combination therapy in hospitalized patients with severe infections. - The study aims to resolve clinical uncertainty about whether VPT causes more acute kidney injury compared to alternative antibiotic regimens, using advanced kidney function testing with serum cystatin C as the primary outcome. - Approximately 1,000 hospitalized adult patients will be enrolled across over two dozen sites nationwide, with the research designed to provide evidence-based guidance for antibiotic selection in severe infections. - The trial addresses a critical evidence gap that currently leads to practice variation among clinicians when choosing between VPT and non-VPT antibiotic regimens for treating serious infections.
- A first-of-its-kind study by OHSU and National University of Natural Medicine found that low-income adults with major depressive disorder experienced significant depression reduction following group psilocybin therapy sessions. - Nineteen participants completed two psilocybin administration sessions and showed sustained improvements three months later, with average satisfaction ratings of 4.8 out of 5. - The group therapy model cost $11,000 total for all participants compared to $4,500 per individual session, potentially making the breakthrough therapy more accessible despite current insurance barriers. - Researchers reported no serious adverse events during the study, with only minor temporary side effects like nausea and headaches observed in some participants.
- Researchers analyzed 678 AML patients and found that both gene mutations and leukemia cell maturity affect response to venetoclax plus hypomethylating agents treatment. - Patients with monocytic AML lacking the NPM1 mutation were nearly twice as likely to die from the disease compared to other patient groups. - The findings offer doctors a new risk classification system to better predict treatment response and guide personalized therapy decisions for AML patients. - This research represents a major step toward personalized medicine in AML by combining genetic and cellular factors to optimize treatment selection.
- Precede Biosciences has developed a comprehensive epigenomic liquid biopsy platform capable of predicting expression of over 2,500 tumor-specific genes from just 1mL of blood plasma. - The technology enables detection of key therapeutic targets including NECTIN4, B7H4, HER3, and transcriptional regulators like AR and FOXA1, potentially transforming precision medicine approaches. - Experts suggest this breakthrough could significantly improve patient-therapy matching, particularly when traditional biopsies aren't feasible or when actionable targets are driven by expression rather than mutations.
- A new JAMA Network Open study reveals that while most OB/GYNs didn't immediately leave states with abortion bans after the 2022 Dobbs ruling, a significant decline is now occurring in the 12 most restrictive states. - Physicians face complex personal and professional decisions about practicing in states with abortion restrictions, weighing patient care needs against potential legal risks to their licenses and freedom. - The migration of maternal-fetal medicine specialists from restrictive states has particularly significant impacts on training and specialized care availability, with some states seeing critical provider shortages.
- A new study reveals significant decreases in oncology medication use after negative confirmatory trials are published, despite drugs remaining available for other indications. - Researchers found that cancer drugs like atezolizumab saw usage drop by 28 patients per million following publication of negative trial results for breast cancer treatment. - The time between accelerated approval and negative trial publication varied widely (12-113 months), highlighting concerns about patient exposure to potentially ineffective treatments.
- The NIH is investing $30 million to launch the CARE for Health network, aimed at integrating clinical research with community-based primary care. - Three inaugural research hubs have been selected at Oregon Health and Science University (OHSU), University of Wisconsin-Madison (UW), and West Virginia University (WVU). - The network will focus on improving access to clinical research for underserved communities and those underrepresented in research. - Initial studies will address chronic back pain, polysubstance abuse, and gout, engaging rural communities through existing NIH-funded trials.
